Peptide Cancer Vaccine Market
Peptide Cancer Vaccine Market - Global Industry Assessment & Forecast
- By Application Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others
- By Type Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine, Others
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
|Forecast Years:||2022 - 2028|
|Historical Years:||2016 - 2021|
|Revenue 2021:||USD 4.72 Billion|
|Revenue 2028:||USD 10.07 Billion|
|Revenue CAGR (2022 - 2028):||11.2%|
|Fastest Growing Region (2022 - 2028)||Asia Pacific|
|Largest Region (2021):||North America|
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Global Peptide Cancer Vaccine market is valued at USD 4.72 Billion in 2021 and is projected to attain a value of USD 10.07 Billion by 2028 at a CAGR of 11.2% during the forecast period, 2022–2028. Peptide Cancer Vaccine help to elicit and grow tumor-specific T lymphocytes that can control or eliminate tumors. One or more short or long amino acid sequences serve as tumor antigens in the vaccination, which is coupled with a vaccine adjuvant.
Clinical experiments using peptide cancer vaccines have yielded disappointing results in the recent past. As a result, peptide vaccine researchers have deemed this therapy obsolete and declared it no longer viable for cancer treatment. However, as knowledge of the crucial function of immunological adjuvants, vaccine administration methods, and T cell dynamics has improved, this approach to the treatment of malignant illnesses has resurfaced.
The rising prevalence of cancer and the failure of traditional cancer treatments to adequately treat the disease has fueled demand for innovative immunotherapy-based therapeutics such Peptide Cancer Vaccine. According to the National Cancer Institute, 16.8 million new instances of cancer were diagnosed in the United States in 2016, with an estimated 595,690 deaths from the disease. By 2024, the number of cancer patients is predicted to reach 19 million. In addition, the World Health Organization (WHO) recorded around 14 million cancer cases and 8.2 million cancer-related deaths in 2012. Lung, colorectal, prostate, cervical, and breast cancer were among the most common occurrences, which has resulted in a substantial increase in demand for peptide vaccines, which has aided in the growth of the Peptide Cancer Vaccine industry.
Peptide Cancer Vaccine Market Size, 2021 To 2028 (USD Billion)
Cost-effective and Easy to Prepare
Furthermore, the ease of synthesizing, cost-effectiveness, and ease of preparation of Peptide Cancer Vaccine, as well as their application in clinical practise, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis, are expected to drive the Peptide Cancer Vaccine market forward in the near future. As a result of these benefits, manufacturers are concentrating their efforts on research in order to develop Peptide Cancer Vaccine. For example, Boston Biomedical, Inc., a company focused on next-generation cancer therapies, began dosing the first patient in each of two clinical studies in April 2018 to assess the efficacy of DSP-7888, an investigational Peptide Cancer Vaccine.
Shortage of Cancer Vaccines
There are a number of limits and limitations that will limit market expansion. Factors such as a lack of cancer vaccinations in distant places and the necessity for specialized storage and transportation are possible barriers to the worldwide Peptide Cancer Vaccine market's overall expansion. Nonetheless, rising public knowledge of cancer diseases, increased government and private sector investment, and untapped potential in emerging economies all point to promising growth prospects.
The Global Peptide Cancer Vaccine Market can be segmented by Application into Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Gastric Cancer, Prostate Cancer and Breast Cancer. Based on Type, into Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine and Others. Based on Region, the Peptide Cancer Vaccine Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Peptide Cancer Vaccine Market
In 2021, North America held the greatest proportion of the global market for Peptide Cancer Vaccine, followed by Europe. The presence of a large number of prominent pharmaceutical and biotech businesses in this region, such as Pfizer, Inc., Novartis, Merck, GlaxoSmithKline, and Roche, is linked to this. Furthermore, the rising prevalence of cancer is likely to boost Peptide Cancer Vaccine market growth.
USD 1.89 Billion
Major players operating in the global Peptide Cancer Vaccine market include TapImmune (US), Merck (US), BrightPath Biotherapeutics (Japan), Sellas (US), BioLife Science (US), Boston Biomedical (US), VAXON Biotech (France), Lytix Biopharma (Norway), ISA Pharmaceuticals (Netherlands), Generex Biotechnology (Canada), OncoTherapy Science (Japan), Enzo Life Science (US), Antigen Express (US), Immatics Biotechnologies (US), Immune Design (US), Immunomedics (US), Galena Biopharma (US), Generex Biotechnology Corporation (Canada), and Ultimovacs (Norway).
The Peptide Cancer Vaccine market is segmented as follows:
Regions & Countries Covered
Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
- Breast Cancer
- Lung Cancer
- Prostate Cancer
By Type (Revenue: USD Billion, 2016 - 2028)
- Personalized Peptide Vaccine
- Peptide-Pulsed Dendritic Cancer Vaccine
- Peptide Cocktail Type
- Multivalent Peptide Vaccine
By Region (Revenue: USD Billion, 2016 - 2028)
- North America
o Rest of Europe
- Asia Pacific
o South Korea
o South East Asia
o Rest of Asia Pacific
- Latin America
o Rest of Latin America
- Middle East & Africa
o GCC Countries
o South Africa
o Rest of Middle East & Africa
Frequently Asked Question
The global Peptide Cancer Vaccine valued at USD 4.72 Billion in 2020 and is expected to reach USD 10.07 Billion in 2028 growing at a CAGR of 11.2%.
The prominent players in the market are TapImmune (US), Merck (US), BrightPath Biotherapeutics (Japan), Sellas (US), BioLife Science (US), Boston Biomedical (US), VAXON Biotech (France), Lytix Biopharma (Norway), ISA Pharmaceuticals (Netherlands), Generex Biotechnology (Canada), OncoTherapy Science (Japan), Enzo Life Science (US), Antigen Express (US), Immatics Biotechnologies (US), Immune Design (US), Immunomedics (US), Galena Biopharma (US), Generex Biotechnology Corporation (Canada), and Ultimovacs (Norway)..
The market is project to grow at a CAGR of 11.2% between 2021 and 2028.
The driving factors of the Peptide Cancer Vaccine include
- Cost-Effective and Easy to Prepare
North America was the leading regional segment of the Peptide Cancer Vaccine in 2020.